T-lymphocytes and broader immune cell populations

T-lymphocytes and broader immune cell populations represent the cellular components of the human immune system, including both adaptive and innate branches (NIH, 2024). T-lymphocytes, or T cells, are defined by the presence of a T-cell receptor (TCR) and play central roles in cell-mediated immunity, while broader populations include B cells, natural killer (NK) cells, and myeloid cells (StatPearls, 2023). These cells coordinate the body's response to pathogens and malignancies through complex signaling networks and direct cytotoxic activity. In therapeutic contexts, these cells are not single molecular targets but are the biological entities modulated by drugs to treat cancer, autoimmune disorders, and infections (PubMed, 2022). For example, checkpoint inhibitors activate T cells to attack tumors, while immunosuppressants like cyclosporine inhibit their activity to prevent organ transplant rejection (DrugBank, 2024). Therapeutic manipulation of these cells carries risks such as cytokine release syndrome or severe immunosuppression (StatPearls, 2023). Because this entry describes a diverse group of cell types rather than a specific protein or receptor, it is classified as a cell population rather than a discrete molecular target (UniProt, 2024).

Other names

T cellsImmune cellsLeukocytesWhite blood cellsLymphocytesPeripheral blood mononuclear cells (PBMCs)

Modulation of immune cell activity through binding to specific surface receptors (e.g., TCR, PD-1, CD20) or intracellular pathways (e.g., calcineurin inhibition) to achieve immunostimulation or immunosuppression (StatPearls, 2023; PubMed, 2022).